RE:RE:RE:RE:RE:Not sure what's new?First of all, I believe the news we are seeing has a lot of potential. This can eventually be a very big deal. But most of the points below were in the May 15th news release.
SPCEO1 wrote: I asked the IR officer about the issue of their not really being a lot of new info in this press release and she gave me this thorough response:
While there is not
a lot of new information, I’ve highlighted the key new data below. Additionally and more exciting, we believe the data further validates VM as a key antagonist in treatment-resistant cancers and the potential ability of our SORT1+ Technology to target VM formation.
- Our new data show that the sortilin receptor is significantly overexpressed in the cancer cells involved in the in the formation of the VM structure.
- Our new data demonstrate that sortilin is a key player in the formation of VM structure - silencing sortilin stops the formation of the VM structure for both ovarian and TNBC cancer cells.
- CD 133, a gene associated with Cancer Stem Cells, is increased in the cells forming the VM
- The results of our SORT1+ Technology when conjugate with curcumin demonstrates the versatility of the platform
- And finally, our technology has demonstrated positive activity in other treatment-resistant cancers outside of ovarian and TNBC, including colorectal
Wino115 wrote: Yeah, I get it, but he more or less has to say that and it's his opinion. I'm just saying that in those posters and abstracts, basically all those facts were already released except quantifying the curcumin conjugate numbers. I'm not trying to bash, just shows that the market really isn't watching this and, most likely, anyone buying it up 35% is not someone who read their PR last month. It's. just hot trader money, looking to punt it for a few days on hope, not new facts.
It's more about trying to ascertain who's playing with it this morning, and I doubt it's anyone who's followed it for any time.
palinc2000 wrote: THIS STATEMENT IS NEW...Marsolais has never expressed such enthusiasm..His confidence level is based on something
“We believe that our SORT1+ technology is one of the most promising advances in the treatment of cancer in many years. As our oncology programs progress through clinical development, we hope to continue to demonstrate that our SORT1+ technology could become a new paradigm in cancer treatment,” said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies. quote=scarlet1967]
Wino115 wrote: In reading the poster abstracts, haven't we seen all this mentioned before? I think almost all of this was covered in their last PR on the oncology program. While they didn't state some of the facts like the 50x 100x on TH1901, it was in the graphs.
Don't get me wrong, happy to see a bit of love. But I actually don't see much in this PR that's new -- it's maybe 95% what has already been released, just packaged better for the posters at AACR.
This was mentioned by IR lady based on the post on Stocktwits, I am surprisingly pleased with price action so far now if the rest of her statements re general Nash/hiv Nash programs combined with positive and Intrested engagement by authorities also intrestred Nash analysts waiting around the corner to start their coverage happen to materialize TH is in business big time.
[/quote]